Reactive oxygen species in cancer stem cells of head and neck squamous cancer

Xu Qian; Xiaobo Nie; Wenhao Yao; Konrad Klinghammer; Holger Sudhoff; Andreas M Kaufmann; Andreas E Albers

doi:10.1016/j.semcancer.2018.06.001

Reactive oxygen species in cancer stem cells of head and neck squamous cancer

Semin Cancer Biol. 2018 Dec:53:248-257. doi: 10.1016/j.semcancer.2018.06.001. Epub 2018 Jun 20.

Authors

Xu Qian¹, Xiaobo Nie², Wenhao Yao³, Konrad Klinghammer⁴, Holger Sudhoff⁵, Andreas M Kaufmann⁶, Andreas E Albers⁷

Affiliations

¹ Department of Otorhinolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany; Division of Molecular Diagnostics, Department of Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, PR China; Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Wenzhou, PR China.
² Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Henan University, Kaifeng, PR China.
³ Department of Otorhinolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
⁴ Department of Hematology and Oncology, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
⁵ Department of Otorhinolaryngology, Head and Neck Surgery, Klinikum Bielefeld, Bielefeld, Germany.
⁶ Clinic for Gynecology, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
⁷ Department of Otorhinolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany. Electronic address: andreas.albers@charite.de.

PMID: 29935313
DOI: 10.1016/j.semcancer.2018.06.001

Abstract

One of the greatest challenges in systemic treatment of head and neck squamous cell carcinoma (HNSCC) is a small tumor cell population, namely, cancer stem-like cells (CSC). CSC can regenerate and maintain a heterogenic tumor by their self-renewal capacity. Their potential ability to be more resistant to and survival after chemo- and radiation therapy was also identified. Further studies have shown that reactive oxygen species (ROS) contribute to this CSC-associated resistance. In this review, we focus on the current knowledge of HNSCC-CSC, with regard to ROS as a possible and novel therapeutic approach in targeting CSC.

Keywords: Cancer stem cell; Disulfiram; Head and neck cancer; Nanotherapeutics; Reactive oxygen species.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Squamous Cell / metabolism*
Cisplatin / therapeutic use
Epithelial-Mesenchymal Transition / drug effects
Humans
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / metabolism*
Reactive Oxygen Species / metabolism*
Signal Transduction / drug effects
Squamous Cell Carcinoma of Head and Neck / drug therapy
Squamous Cell Carcinoma of Head and Neck / metabolism*

Substances

Antineoplastic Agents
Reactive Oxygen Species
Cisplatin